- A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 with notable differences observed as early as Week 4
- No treatment-related serious adverse events occurred with SI-6603
- Additional analysis presented at ASPN evaluated economic burden of lumbar disc herniation surgery
PARSIPPANY, NJ. USA I July 15, 2024 I Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of a Phase 3 data analysis evaluating the early treatment response to SI-6603 (generic name: condoliase), an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH). The research, presented at the American Society of Pain and Neuroscience (ASPN) Annual Meeting, also included an analysis of healthcare resource utilization and costs associated with LDH surgery.
In the analysis (poster number 44) of the double-blind, sham-controlled, Phase 3 study, patients with LDH were randomized to receive either a single intradiscal injection of SI-6603 1.25 Units or a sham injection, followed by 52 weeks of observation (Weeks 1, 2, 4, 6, 13, 26, 39, 52). The modified intention-to-treat (mITT) population included 341 participants (SI-6603 n=169; sham n=172). The study met its primary endpoint, showing significantly greater improvement vs. sham in worst leg pain at Week 13 (least squares mean [LSM] difference: -7.5; p=0.0263) with notable differences as early as Week 4 (-6.0; p=0.0418) and Week 6 (-7.4; p=0.0146).
Beginning at Week 1, more participants in the SI-6603 group vs. sham had a negative straight leg raise test (p=0.0054) which was sustained to Week 52 (p=0.0003). Notable differences in 50% responders for worst leg pain (i.e., meaning a ≥50% improvement from baseline) also favored SI-6603 vs. sham at Week 4 (p=0.0189), Week 6 (p=0.0297) and Week 13 (p=0.0165). There were no treatment-related serious adverse events with SI-6603.
“The early treatment response observed in this analysis is promising for those suffering from radicular leg pain resulting from lumbar disc herniation and who may experience severe, debilitating pain which can affect their mobility, and impact their ability to go about their usual activities. This is an area of significant unmet patient need and if approved, SI-6603, which targets the source of radicular leg pain, may help fill a current treatment gap between conservative pain management and surgery,” said Raza Ahmed, MD, Senior Director, Medical Affairs, Specialty/Orthopaedics, Ferring USA.
An analysis (poster number 171) of healthcare resource utilization and costs for patients with LDH who underwent LDH surgical procedures was also presented at ASPN 2024. Of the more than one million patients with LDH in the medical claims database, 58,328 underwent LDH surgeries within one year of initial diagnosis.
During the first year following initial diagnosis, patients treated with surgery had more LDH-related outpatient visits than non-surgery-treated patients (mean: 17.0 vs. 10.3) and a higher proportion of LDH-related hospitalizations (36.3% vs. 0.9%). Nearly half (48.2%) of surgery-treated patients received at least one epidural steroid injection (ESI) within the first year, with 49% of them receiving multiple ESIs. Total LDH-related healthcare cost during the first year was $35,018 for surgery-treated patients versus $4,384 for non-surgery-treated patients. The average cost for LDH surgery was $25,993 per procedure ($25,815 for the first surgery and $27,587 for subsequent procedures). About one in three LDH surgeries (35.7%) were performed in an inpatient setting, with a cost three times higher than an outpatient setting ($46,411 vs. $14,666).
About the Phase 3 Trial Data Analysis
In this double-blind, sham-controlled, parallel Phase 3 study — known as the Discovery 6603 clinical trial (NCT03607838) — participants were randomized 1:1 to receive either SI-6603 (1.25 U) or sham injection followed by 52 weeks of observation. The primary endpoint was defined as the change from baseline to Week 13 in average worst leg pain during the past 24 hours over the previous seven days, as assessed by Visual Analogue Scale, a pain rating score from 0 – 100 with a higher score indicating greater pain intensity. Key secondary endpoints included the change from baseline in average worst leg pain at 52 weeks, percentage of participants with negative straight leg raise test, and 50% responder rates for worst leg pain and Oswestry Disability Index. Endpoints were assessed using a mixed model for repeated measures analysis on the modified intention-to-treat population, which represented all randomized participants who received the study injection analyzed according to the assigned treatment. Missing data was handled using a mixed-effect model, without explicit imputation.
The trial included U.S. participants ages 30 to 70 years old who had contained posterolateral LDH with the chief complaint being unilateral radiculopathy/radicular leg pain and inadequate improvement in pain despite more than six weeks of conservative treatment. Among 352 randomized participants, 341 constituted the mITT population (SI-6603 n=169; sham injections n=172).
About the Healthcare Utilization and LDH Surgery Analysis
For this study, investigators reviewed medical claims data from the IQVIA PharMetrics® Plus database of 1,086,552 adults ages 30 to 70 years diagnosed with LDH between 01/01/2018 and 03/31/2022. Eligible patients had continuous medical and pharmacy enrollment for at least 6 months before and 12 months after the initial diagnosis. Among the patients with LDH, 58,328 patients underwent LDH surgeries within one year of initial diagnosis. On average, these patients were approximately 52 years old (51.9±9.9) with most comorbidities that were mild to moderate in severity, based on a mean Charlson Comorbidity Index score of 1.3±1.8.
About Lumbar Disc Herniation
About 9 million adults in the U.S. suffer from lumbar disc herniation each year. A disc herniation is a displacement (leakage) of the gel-like inner core of the intervertebral disc, called the nucleus pulposus, through its external membrane (annulus fibrosus) due to wear and tear, aging or sudden injury. As a result of this displacement, the disc presses on the spinal nerve, often producing pain.1,2
About SI-6603
SI-6603, which contains condoliase as its active pharmaceutical ingredient, is an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation via a single, direct intradiscal injection. SI-6603 (condoliase) reduces nerve root compression and thereby pain.
SI-6603 was developed by Seikagaku. Marketing approval for SI-6603 in Japan was obtained from the Japanese Ministry of Health, Labour and Welfare in March 2018 and SI-6603 has been marketed in Japan only as HERNICORE® 1.25 units for intradiscal injection through Seikagaku Corporation’s Japanese sales partner Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) since August 1, 2018.3
Alliance with Seikagaku
Seikagaku and Ferring entered into a license agreement for SI-6603 in August 2016. Ferring plans to commercialize the product in the United States and has received further rights to develop, register and commercialize SI-6603 worldwide, excluding Japan.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
For more information, please visit www.ferringusa.com, call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn and X (Twitter).
References:
1 Vialle LR, Vialle EN, Suárez Henao JE, Giraldo G. Lumbar Disc Herniation. Rev Bras Ortop. 2015 Nov 16;45(1):17-22. doi: 10.1016/S2255-4971(15)30211-1. PMID: 27019834; PMCID: PMC4799068.
2 Herniated Disk in the Lower Back. OrthoInfo. American Academy of Orthopaedic Surgeons. Available at: https://orthoinfo.aaos.org/en/diseases–conditions/herniated-disk-in-the-lower-back/. Accessed May 23, 2023.
3 Press Release. Seikagaku and Kaken Announce the Launch of HERNICORE® 1.25 Units for Intradiscal Injection in Japan. July 31,2018. Available at: https://www.seikagaku.co.jp/en/news/news-6617037418084939174/main/0/link/20180731-e.pdf. Accessed May 24, 2023.
SOURCE: Ferring Pharmaceuticals
Post Views: 6,903
- A single intradiscal injection of SI-6603 demonstrated significantly greater improvement in leg pain vs. sham at Week 13 with notable differences observed as early as Week 4
- No treatment-related serious adverse events occurred with SI-6603
- Additional analysis presented at ASPN evaluated economic burden of lumbar disc herniation surgery
PARSIPPANY, NJ. USA I July 15, 2024 I Ferring Pharmaceuticals and its clinical development partner, Seikagaku Corporation (Seikagaku), today announced the presentation of a Phase 3 data analysis evaluating the early treatment response to SI-6603 (generic name: condoliase), an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH). The research, presented at the American Society of Pain and Neuroscience (ASPN) Annual Meeting, also included an analysis of healthcare resource utilization and costs associated with LDH surgery.
In the analysis (poster number 44) of the double-blind, sham-controlled, Phase 3 study, patients with LDH were randomized to receive either a single intradiscal injection of SI-6603 1.25 Units or a sham injection, followed by 52 weeks of observation (Weeks 1, 2, 4, 6, 13, 26, 39, 52). The modified intention-to-treat (mITT) population included 341 participants (SI-6603 n=169; sham n=172). The study met its primary endpoint, showing significantly greater improvement vs. sham in worst leg pain at Week 13 (least squares mean [LSM] difference: -7.5; p=0.0263) with notable differences as early as Week 4 (-6.0; p=0.0418) and Week 6 (-7.4; p=0.0146).
Beginning at Week 1, more participants in the SI-6603 group vs. sham had a negative straight leg raise test (p=0.0054) which was sustained to Week 52 (p=0.0003). Notable differences in 50% responders for worst leg pain (i.e., meaning a ≥50% improvement from baseline) also favored SI-6603 vs. sham at Week 4 (p=0.0189), Week 6 (p=0.0297) and Week 13 (p=0.0165). There were no treatment-related serious adverse events with SI-6603.
“The early treatment response observed in this analysis is promising for those suffering from radicular leg pain resulting from lumbar disc herniation and who may experience severe, debilitating pain which can affect their mobility, and impact their ability to go about their usual activities. This is an area of significant unmet patient need and if approved, SI-6603, which targets the source of radicular leg pain, may help fill a current treatment gap between conservative pain management and surgery,” said Raza Ahmed, MD, Senior Director, Medical Affairs, Specialty/Orthopaedics, Ferring USA.
An analysis (poster number 171) of healthcare resource utilization and costs for patients with LDH who underwent LDH surgical procedures was also presented at ASPN 2024. Of the more than one million patients with LDH in the medical claims database, 58,328 underwent LDH surgeries within one year of initial diagnosis.
During the first year following initial diagnosis, patients treated with surgery had more LDH-related outpatient visits than non-surgery-treated patients (mean: 17.0 vs. 10.3) and a higher proportion of LDH-related hospitalizations (36.3% vs. 0.9%). Nearly half (48.2%) of surgery-treated patients received at least one epidural steroid injection (ESI) within the first year, with 49% of them receiving multiple ESIs. Total LDH-related healthcare cost during the first year was $35,018 for surgery-treated patients versus $4,384 for non-surgery-treated patients. The average cost for LDH surgery was $25,993 per procedure ($25,815 for the first surgery and $27,587 for subsequent procedures). About one in three LDH surgeries (35.7%) were performed in an inpatient setting, with a cost three times higher than an outpatient setting ($46,411 vs. $14,666).
About the Phase 3 Trial Data Analysis
In this double-blind, sham-controlled, parallel Phase 3 study — known as the Discovery 6603 clinical trial (NCT03607838) — participants were randomized 1:1 to receive either SI-6603 (1.25 U) or sham injection followed by 52 weeks of observation. The primary endpoint was defined as the change from baseline to Week 13 in average worst leg pain during the past 24 hours over the previous seven days, as assessed by Visual Analogue Scale, a pain rating score from 0 – 100 with a higher score indicating greater pain intensity. Key secondary endpoints included the change from baseline in average worst leg pain at 52 weeks, percentage of participants with negative straight leg raise test, and 50% responder rates for worst leg pain and Oswestry Disability Index. Endpoints were assessed using a mixed model for repeated measures analysis on the modified intention-to-treat population, which represented all randomized participants who received the study injection analyzed according to the assigned treatment. Missing data was handled using a mixed-effect model, without explicit imputation.
The trial included U.S. participants ages 30 to 70 years old who had contained posterolateral LDH with the chief complaint being unilateral radiculopathy/radicular leg pain and inadequate improvement in pain despite more than six weeks of conservative treatment. Among 352 randomized participants, 341 constituted the mITT population (SI-6603 n=169; sham injections n=172).
About the Healthcare Utilization and LDH Surgery Analysis
For this study, investigators reviewed medical claims data from the IQVIA PharMetrics® Plus database of 1,086,552 adults ages 30 to 70 years diagnosed with LDH between 01/01/2018 and 03/31/2022. Eligible patients had continuous medical and pharmacy enrollment for at least 6 months before and 12 months after the initial diagnosis. Among the patients with LDH, 58,328 patients underwent LDH surgeries within one year of initial diagnosis. On average, these patients were approximately 52 years old (51.9±9.9) with most comorbidities that were mild to moderate in severity, based on a mean Charlson Comorbidity Index score of 1.3±1.8.
About Lumbar Disc Herniation
About 9 million adults in the U.S. suffer from lumbar disc herniation each year. A disc herniation is a displacement (leakage) of the gel-like inner core of the intervertebral disc, called the nucleus pulposus, through its external membrane (annulus fibrosus) due to wear and tear, aging or sudden injury. As a result of this displacement, the disc presses on the spinal nerve, often producing pain.1,2
About SI-6603
SI-6603, which contains condoliase as its active pharmaceutical ingredient, is an investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation via a single, direct intradiscal injection. SI-6603 (condoliase) reduces nerve root compression and thereby pain.
SI-6603 was developed by Seikagaku. Marketing approval for SI-6603 in Japan was obtained from the Japanese Ministry of Health, Labour and Welfare in March 2018 and SI-6603 has been marketed in Japan only as HERNICORE® 1.25 units for intradiscal injection through Seikagaku Corporation’s Japanese sales partner Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) since August 1, 2018.3
Alliance with Seikagaku
Seikagaku and Ferring entered into a license agreement for SI-6603 in August 2016. Ferring plans to commercialize the product in the United States and has received further rights to develop, register and commercialize SI-6603 worldwide, excluding Japan.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
For more information, please visit www.ferringusa.com, call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn and X (Twitter).
References:
1 Vialle LR, Vialle EN, Suárez Henao JE, Giraldo G. Lumbar Disc Herniation. Rev Bras Ortop. 2015 Nov 16;45(1):17-22. doi: 10.1016/S2255-4971(15)30211-1. PMID: 27019834; PMCID: PMC4799068.
2 Herniated Disk in the Lower Back. OrthoInfo. American Academy of Orthopaedic Surgeons. Available at: https://orthoinfo.aaos.org/en/diseases–conditions/herniated-disk-in-the-lower-back/. Accessed May 23, 2023.
3 Press Release. Seikagaku and Kaken Announce the Launch of HERNICORE® 1.25 Units for Intradiscal Injection in Japan. July 31,2018. Available at: https://www.seikagaku.co.jp/en/news/news-6617037418084939174/main/0/link/20180731-e.pdf. Accessed May 24, 2023.
SOURCE: Ferring Pharmaceuticals
Post Views: 6,903
